Neuralink Announces Expansion of Clinical Trial to 21 Participants Globally

Gelonghui, January 29 | Neuralink, the brain-computer interface company under Elon Musk, stated on Wednesday that two years after officially commencing human trials, it currently has 21 participants in its global clinical trials, an increase from 12 in September last year. At that time, these participants had already received its implant and used it to control both digital and physical devices through thought. The company indicated that it is collaborating with regulatory authorities and hospitals to provide participants with improved devices, while maintaining its record of no serious device-related adverse events to date.